流式细胞术在成熟B细胞非霍奇金淋巴瘤诊断和微小残留病检测中的应用中国专家共识(2025年版)  

Chinese expert consensus on the application of flow cytometry in the diagnosis and detection of minimal residual disease in B-cell non-Hodgkin lymphoma(2025)

作　　者：中国抗癌协会血液肿瘤专业委员会 中华医学会血液学分会 中国慢性淋巴细胞白血病工作组 易树华 范磊[3] 纪春岩[4] 吴雨洁 翁香琴[6] 王慧君 叶静静[8] Hematological Oncology Committee of China Anti-Cancer Association;Chinese Society of Hematology,Chinese Medical Association;Chinese Working Group for Chronic Lymphocytic Leukemia;Yi Shuhua;Fan Lei;Ji Chunyan(不详;Institute of Hematology&Blood Diseases Hospital,CAMS&PUMC,Tianjin 300020,China;Fan Lei;Department of Hematology,Qilu Hospital of Shandong University,Jinan 250012,China)

机构地区：[1]不详 [2]中国医学科学院血液病医院(中国医学科学院血液学研究所),天津300020 [3]南京医科大学第一附属医院血液科,南京210029 [4]山东大学齐鲁医院血液科,济南250012 [5]南京医科大学第一附属医院 [6]上海交通大学医学院附属瑞金医院 [7]中国医学科学院血液病医院 [8]山东大学齐鲁医院

出　　处：《中华血液学杂志》2025年第2期113-119,共7页Chinese Journal of Hematology

摘　　要：B细胞非霍奇金淋巴瘤(B-cell non-Hodgkin lymphoma,B-NHL)包含多种亚型,精准诊断依赖于多学科合作,包括病理形态学、免疫组织化学、流式细胞术(FCM)、细胞遗传学、分子生物学、影像学与临床特征等。FCM以其操作简单、快速、客观、灵敏度高和多参数分析等独特优势,在B-NHL的诊断和微小残留病(MRD)检测中发挥着不可替代的作用。随着第5版WHO造血与淋巴组织肿瘤分类和国际共识分类(ICC)的陆续发表,B-NHL中不同亚类的分型更加细化,一些分类方法和命名方式也发生了较大变化。为了提高B-NHL的诊断和治疗监测水平,规范我国对此类疾病的诊治程序,中国抗癌协会血液肿瘤专业委员会组织国内相关领域的专家经过多次讨论后,针对FCM在成熟B-NHL诊断和MRD检测中的应用,包括FCM样本来源与制备、不同亚类B-NHL免疫表型特点、结果分析与报告以及质量控制四方面制订了本专家共识。B-cell non-Hodgkin lymphoma(B-NHL)is made up of multiple subtypes,whose precise diagnosis relies on multidisciplinary collaboration,including pathological morphology,immunohistochemistry,flow cytometry(FCM),cytogenetics,molecular biology,imaging and clinical features.FCM plays an irreplaceable role in the diagnosis of B-NHL and minimal/measurable residual disease(MRD)monitoring due to its unique advantages of simplicity,rapidness,objectivity,high sensitivity,and multi-parameter analysis.With the publication of the 5th edition of the World Health Organization(WHO)Classification of Haematolymphoid Tumours and the International Consensus Classification(ICC),the classification of B-NHL has become more refined,with significant changes in some classification methods and nomenclature.To improve the diagnostic and therapeutic monitoring ability of B-NHL and standardize the diagnosis and treatment procedures of B-NHL in China,the Hematological Oncology Committee of the China Anti-Cancer Association organized relevant domestic experts to develop this expert consensus after multiple discussions.The consensus focuses on the application of FCM in the diagnosis and MRD detection of mature B-NHL including the sources and preparation of samples for FCM,the immunophenotypic characteristics of different subclasses of B-NHL,result analysis and reporting,and quality control.

关 键 词：专家共识 样本来源 微小残留病 免疫表型 制备 

分 类 号：R733.1[医药卫生—肿瘤]